Back to News
Market Impact: 0.18
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
Source: marketbeat.com
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Equillium's chief scientific officer outlined plans to advance its lead clinical programs: an oral AhR modulator for ulcerative colitis and an oral bispecific peptide for celiac disease. The update signals continued pipeline development but provided no clinical data, regulatory milestones, or financial guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
EQ0.35
More News
- Here are the 4 big things we're watching in the stock market in the week ahead
- Paramount Warner Deal Tests Hollywood’s Future
- OpenAI, Anthropic CEOs called to appear at Australian AI probe
- Why Meta Platforms Stock Jumped 13% This Week
- When the Government Becomes Your Co-Investor
- I'd Buy Amazon Stock While It Sits 12% Below Its Record